{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:28:03Z","timestamp":1791052083682,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s12325-009-0075-9","type":"journal-article","created":{"date-parts":[[2009,12,4]],"date-time":"2009-12-04T05:38:58Z","timestamp":1259905138000},"page":"920-935","source":"Crossref","is-referenced-by-count":77,"title":["Skin tolerability associated with transdermal drug delivery systems: an overview"],"prefix":"10.1007","volume":"26","author":[{"given":"Iris","family":"Ale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Lachapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard I.","family":"Maibach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,27]]},"reference":[{"key":"75_CR1","first-page":"101","volume-title":"Marzulli and Maibach\u2019s Dermato-toxicology","author":"C. Levin","year":"2008","unstructured":"Levin C, Maibach HI. Transdermal drug delivery system: an overview. In: Zhai H, Wilhelm K-P, Maibach HI, eds. Marzulli and Maibach\u2019s Dermato-toxicology. 7th edition. Boca Raton, FL: CRC Press; 2008:101\u2013106.","edition":"7"},{"key":"75_CR2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0625.2000.009003165.x","volume":"9","author":"J.D. Bos","year":"2000","unstructured":"Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9:165\u2013169.","journal-title":"Exp Dermatol"},{"key":"75_CR3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0169-409X(01)00113-2","volume":"48","author":"Y.N. Kalia","year":"2001","unstructured":"Kalia YN, Guy RH. Modeling transdermal drug release. Adv Drug Deliv Rev. 2001;48:159\u2013172.","journal-title":"Adv Drug Deliv Rev"},{"key":"75_CR4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.urology.2005.11.039","volume":"67","author":"V.W. Nitti","year":"2006","unstructured":"Nitti VW, Sanders S, Staskin DR, et al. Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology. 2006;67:657\u2013664.","journal-title":"Urology"},{"key":"75_CR5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.17925\/ENR.2008.03.01.10","volume":"3","author":"R. Bernabei","year":"2008","unstructured":"Bernabei R, Mart\u00ednez Lage P. Clinical benefits associated with a transdermal patch for dementia. Eur Neurol Rev. 2008;3:10\u201313.","journal-title":"Eur Neurol Rev"},{"key":"75_CR6","unstructured":"Transderm Scop Patch (scopolamine 1.5 mg) [prescribing information]. Parsippany, NJ: Novartis. February 2006. Available at: http:\/\/www.transdermscop.com\/prescribing-information.htm . Accessed October 2009."},{"key":"75_CR7","unstructured":"Exelon Patch (rivastigmine transdermal system): How does the Exelon Patch work? Available at: http:\/\/www.exelonpatch.com\/info\/How_the_Exelon_Patch_Can_Help\/How-exelon-patch-works.jsp . Accessed April 2009."},{"key":"75_CR8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00128071-200001060-00004","volume":"1","author":"M. Murphy","year":"2000","unstructured":"Murphy M, Carmichael AJ. Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management. Am J Clin Dermatol. 2000;1:361\u2013368.","journal-title":"Am J Clin Dermatol"},{"key":"75_CR9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0536.1989.tb03087.x","volume":"20","author":"M.R. Holdiness","year":"1989","unstructured":"Holdiness MR. A review of contact dermatitis associated with transdermal therapeutic systems. Contact Dermatitis. 1989;20:3\u20139.","journal-title":"Contact Dermatitis"},{"key":"75_CR10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0190-9622(90)70113-V","volume":"22","author":"D.J. Hogan","year":"1990","unstructured":"Hogan DJ, Maibach HI. Adverse dermatologic reactions to transdermal drug delivery systems. J Am Acad Dermatol. 1990;22:811\u2013814.","journal-title":"J Am Acad Dermatol"},{"key":"75_CR11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2165\/00002512-200623050-00001","volume":"23","author":"L. Priano","year":"2006","unstructured":"Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging. 2006;23:357\u2013375.","journal-title":"Drugs Aging"},{"key":"75_CR12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0928-0987(01)00167-1","volume":"14","author":"B.W. Barry","year":"2001","unstructured":"Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001;14:101\u2013114.","journal-title":"Eur J Pharm Sci"},{"key":"75_CR13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0304-3959(98)00244-9","volume":"80","author":"B.S. Galer","year":"1999","unstructured":"Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80:533\u2013538.","journal-title":"Pain"},{"key":"75_CR14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4088\/JCP.v69n0120","volume":"69","author":"R.L. Findling","year":"2008","unstructured":"Findling RL, Bukstein OG, Melmed RD, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit\/hyperactivity disorder. J Clin Psychiatry. 2008;69:149\u2013159.","journal-title":"J Clin Psychiatry"},{"key":"75_CR15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2006.11.033","volume":"51","author":"R. Cartwright","year":"2007","unstructured":"Cartwright R, Cardozo L. Transdermal oxybutynin: sticking to the facts. Eur Urol. 2007;51:907\u2013914.","journal-title":"Eur Urol"},{"key":"75_CR16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","volume":"68","author":"R.L. Watts","year":"2007","unstructured":"Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272\u2013276.","journal-title":"Neurology"},{"key":"75_CR17","first-page":"58","volume":"23","author":"R. Schmidt","year":"2009","unstructured":"Schmidt R, Alf C, Bancher C, et al. Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia. Neuropsychiatry. 2009;23:58\u201363.","journal-title":"Neuropsychiatry"},{"key":"75_CR18","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1176\/appi.ajp.159.11.1869","volume":"159","author":"J.A. Bodkin","year":"2002","unstructured":"Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159:1869\u20131875.","journal-title":"Am J Psychiatry"},{"key":"75_CR19","first-page":"155","volume-title":"Marzulli and Maibach\u2019s Dermatotoxicology","author":"F.N. Marzulli","year":"2008","unstructured":"Marzulli FN, Maibach HI. Allergic contact dermatitis. In: Zhai H, Wilhelm K-P, Maibach HI, eds. Marzulli and Maibach\u2019s Dermatotoxicology. 7th edition. Boca Raton, FL: CRC Press; 2008:155\u2013158.","edition":"7"},{"key":"75_CR20","first-page":"125","volume-title":"Marzulli and Maibach\u2019s Dermatotoxicology","author":"S. Weltfriend","year":"2008","unstructured":"Weltfriend S, Maibach HI. Irritant dermatitis: clinical heterogeneity and contributing factors. In: Zhai H, Wilhelm K-P, Maibach HI, eds. Marzulli and Maibach\u2019s Dermatotoxicology. 7th edition. Boca Raton, FL: CRC Press; 2008:125\u2013138.","edition":"7"},{"key":"75_CR21","volume-title":"A Practical Guide","author":"J.M. Lachapelle","year":"2009","unstructured":"Lachapelle JM, Maibach HI. Patch Testing and Prick Testing. A Practical Guide. 2nd edition. Berlin Heidelberg: Springer; 2009.","edition":"2"},{"key":"75_CR22","first-page":"209","volume-title":"Marzulli and Maibach\u2019s Dermatotoxicology","author":"N.M. Moulton-Levy","year":"2008","unstructured":"Moulton-Levy NM, Maibach HI. Photoirritation (phototoxicity, phototoxic dermatitis). In: Zhai H, Wilhelm K-P, Maibach HI, eds. Marzulli and Maibach\u2019s Dermatotoxicology. 7th edition. Boca Raton: CRC Press; 2008:209\u2013214.","edition":"7"},{"key":"75_CR23","unstructured":"Lidoderm (lidocaine patch 5%) [prescribing information]. Chadds Ford, PA; Endo Pharmaceuticals, Inc. February 2008. Available at: http:\/\/www.lido-derm.com\/prescrib.aspx . Accessed April 2009."},{"key":"75_CR24","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/01.chi.0000157548.48960.95","volume":"44","author":"W.E. Pelham Jr.","year":"2005","unstructured":"Pelham WE Jr., Manos MJ, Ezzell CE, et al. A doseranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44:522\u2013529.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"75_CR25","unstructured":"Daytrana (methylphenidate transdermal system) [prescribing information]. Wayne, PA: Shire US Inc. January 2008. Available at: http:\/\/www.daytrana.com\/prescribing-information . Accessed April 2009."},{"key":"75_CR26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0090-4295(03)00356-X","volume":"62","author":"R.R. Dmochowski","year":"2003","unstructured":"Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62:237\u2013242.","journal-title":"Urology"},{"key":"75_CR27","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0022-5347(05)64684-8","volume":"168","author":"R.R. Dmochowski","year":"2002","unstructured":"Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168:580\u2013586.","journal-title":"J Urol"},{"key":"75_CR28","unstructured":"Oxytrol patch (oxybutynin transdermal system) [prescribing information]. Corona, CA: Watson Pharmaceuticals, Inc. May 2006. Available at: http:\/\/pi.watson.com\/data_stream.asp?product_group=1295&p=pi&language=E . Accessed April 2009."},{"key":"75_CR29","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","volume":"68","author":"P.A. LeWitt","year":"2007","unstructured":"LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology. 2007;68:1262\u20131267.","journal-title":"Neurology"},{"key":"75_CR30","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/mds.21741","volume":"22","author":"N. Giladi","year":"2007","unstructured":"Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson\u2019s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22:2398\u20132404.","journal-title":"Mov Disord"},{"key":"75_CR31","doi-asserted-by":"crossref","unstructured":"Neupro (rotigotine transdermal system) [prescribing information]. Mequon, WI: Schwarz Pharma, LLC. June 2006. Available at: http:\/\/www.neupro.com\/documents\/Neupro+PI_071207.pdf . Accessed April 2009.","DOI":"10.3833\/pdr.v2006i67.580"},{"key":"75_CR32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1533317509333037","volume":"24","author":"C.H. Sadowsky","year":"2009","unstructured":"Sadowsky CH, Dengiz A, Olin JT, Koumaras B, Meng X, Brannan S. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer\u2019s disease. Am J Alzheimers Dis Other Demen. 2009;24:267\u2013275.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"75_CR33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/gps.1788","volume":"22","author":"B. Winblad","year":"2007","unstructured":"Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer\u2019s disease \u2014 rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22:456\u2013467.","journal-title":"Int J Geriatr Psychiatry"},{"key":"75_CR34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jad.2007.04.024","volume":"105","author":"D.S. Robinson","year":"2008","unstructured":"Robinson DS, Amsterdam JD. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. J Affect Disord. 2008;105:15\u201323.","journal-title":"J Affect Disord"},{"key":"75_CR35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/01.jcp.0000239794.37073.70","volume":"26","author":"J.D. Amsterdam","year":"2006","unstructured":"Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol. 2006;26:579\u2013586.","journal-title":"J Clin Psychopharmacol"},{"key":"75_CR36","unstructured":"Emsam (selegiline transdermal system) [prescribing information]. Princeton, NJ: Bristol Myers Squibb. February 2008. Available at: http:\/\/packageinserts.bms.com\/pi\/pi_emsam.pdf . Accessed April, 2009."},{"key":"75_CR37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/15563657808988241","volume":"13","author":"C.G. Mathias","year":"1978","unstructured":"Mathias CG, Maibach HI. Dermatotoxicology monographs I. Cutaneous irritation: factors infuencing the response to irritants. Clin Toxicol. 1978;13:333\u2013346.","journal-title":"Clin Toxicol"},{"key":"75_CR38","first-page":"923","volume-title":"Marzulli and Maibach\u2019s Dermatotoxicology","author":"A.-L. Chew","year":"2008","unstructured":"Chew A-L, Maibach HI. Classification of irritant dermatitis. In: Zhai H, Wilhelm K-P, Maibach HI, eds. Marzulli and Maibach\u2019s Dermatotoxicology. 7th edition. Boca Raton, FL: CRC Press; 2008:923\u2013926.","edition":"7"},{"key":"75_CR39","first-page":"526","volume":"34","author":"A.A. Fisher","year":"1984","unstructured":"Fisher AA. Dermatitis due to transdermal therapeutic systems. Cutis. 1984;34:526\u2013531.","journal-title":"Cutis"},{"key":"75_CR40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2133.1985.tb02321.x","volume":"112","author":"J.F. Hurkmans","year":"1985","unstructured":"Hurkmans JF, Bodde HE, Van Driel LM, Van Doorne H, Junginger HE. Skin irritation caused by transdermal drug delivery systems during long-term (5 days) application. Br J Dermatol. 1985;112:461\u2013467.","journal-title":"Br J Dermatol"},{"key":"75_CR41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-0536.2008.01367.x","volume":"59","author":"J.P. Thyssen","year":"2008","unstructured":"Thyssen JP, Maibach HI. Drug-elicited systemic allergic (contact) dermatitis \u2014 update and possible pathomechanisms. Contact Dermatitis. 2008;59:195\u2013202.","journal-title":"Contact Dermatitis"},{"key":"75_CR42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1600-0536.1994.tb00594.x","volume":"30","author":"S. Patil","year":"1994","unstructured":"Patil S, Maibach HI. Effect of age and sex on the elicitation of irritant contact dermatitis. Contact Dermatitis. 1994;30:257\u2013264.","journal-title":"Contact Dermatitis"},{"key":"75_CR43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.0909-725X.2005.00151.x","volume":"11","author":"J.M. Waller","year":"2005","unstructured":"Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (I): blood flow, pH, thickness, and ultrasound echogenicity. Skin Res Technol. 2005;11:221\u2013235.","journal-title":"Skin Res Technol"},{"key":"75_CR44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.0909-752X.2006.00146.x","volume":"12","author":"J.M. Waller","year":"2006","unstructured":"Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (II): protein, glycosaminoglycan, water, and lipid content and structure. Skin Res Technol. 2006;12:145\u2013154.","journal-title":"Skin Res Technol"},{"key":"75_CR45","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1600-0536.1995.tb02041.x","volume":"33","author":"C. Kwangsukstith","year":"1995","unstructured":"Kwangsukstith C, Maibach HI. Effect of age and sex on the induction and elicitation of allergic contact dermatitis. Contact Dermatitis. 1995;33:289\u2013298.","journal-title":"Contact Dermatitis"},{"key":"75_CR46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002510050032","volume":"51","author":"M.H. Allen","year":"2000","unstructured":"Allen MH, Wakelin SH, Holloway D, et al. Association of TNFA gene polymorphism at position \u2212308 with susceptibility to irritant contact dermatitis. Immunogenetics. 2000;51:201\u2013205.","journal-title":"Immunogenetics"},{"key":"75_CR47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-0536.1986.tb01198.x","volume":"14","author":"D.J. Gawkrodger","year":"1986","unstructured":"Gawkrodger DJ, Vestey JP, Wong WK, Buxton PK. Contact clinic survey of nickel-sensitive subjects. Contact Dermatitis. 1986;14:165\u2013169.","journal-title":"Contact Dermatitis"},{"key":"75_CR48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1034\/j.1600-0536.2001.044004201.x","volume":"44","author":"H. Zhai","year":"2001","unstructured":"Zhai H, Maibach HI. Skin occlusion and irritant and allergic contact dermatitis: an overview. Contact Dermatitis. 2001;44:201\u2013206.","journal-title":"Contact Dermatitis"},{"key":"75_CR49","first-page":"449","volume-title":"Clinical Tropical Dermatology","author":"A. Okoro","year":"1992","unstructured":"Okoro A, Rook AJ, Canizares O. Chapter 23. Eczemas in the tropics. Plant dermatitis. In: Canizares O, Harman R, eds. Clinical Tropical Dermatology. 2nd edition. Boston, MA: Blackwell Scientific Publications; 1992:449\u2013481.","edition":"2"},{"key":"75_CR50","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/0091270006297748","volume":"47","author":"G. Lef\u00e8vre","year":"2007","unstructured":"Lef\u00e8vre G, Sedek G, Huang HL, et al. Pharmaco-kinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol. 2007;47:471\u2013478.","journal-title":"J Clin Pharmacol"},{"key":"75_CR51","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1001\/archderm.1987.01660350099022","volume":"123","author":"C. Nieboer","year":"1987","unstructured":"Nieboer C, Bruynzeel DP, Boorsma DM. The effect of occlusion of the skin with transdermal therapeutic system on Langerhans\u2019 cells and the induction of skin irritation. Arch Dermatol. 1987;123:1499\u20131502.","journal-title":"Arch Dermatol"},{"key":"75_CR52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/00015550152384227","volume":"81","author":"E. Held","year":"2001","unstructured":"Held E, Agner T. Effect of moisturizers on skin susceptibility to irritants. Acta Derm Venereol. 2001;81:104\u2013107.","journal-title":"Acta Derm Venereol"},{"key":"75_CR53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1034\/j.1600-0536.2001.044004229.x","volume":"44","author":"E. Held","year":"2001","unstructured":"Held E, Lund H, Agner T. Effect of different moisturizers on SLS-irritated human skin. Contact Dermatitis. 2001;44:229\u2013234.","journal-title":"Contact Dermatitis"},{"key":"75_CR54","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1365-2133.2004.06145.x","volume":"151","author":"L. Kynemund Pedersen","year":"2004","unstructured":"Kynemund Pedersen L, Agner T, Held E, Johansen JD. Methyldibromoglutaronitrile in leave-on products elicits contact allergy at low concentration. Br J Dermatol. 2004;151:817\u2013822.","journal-title":"Br J Dermatol"},{"key":"75_CR55","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0190-9622(96)90491-0","volume":"35","author":"A.A. Amkraut","year":"1996","unstructured":"Amkraut AA, Jordan WP, Taskovich L. Effect of coadministration of corticosteroids on the development of contact sensitization. J Am Acad Dermatol. 1996;35:27\u201331.","journal-title":"J Am Acad Dermatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-009-0075-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-009-0075-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-009-0075-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T07:55:56Z","timestamp":1559462156000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-009-0075-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["75"],"URL":"https:\/\/doi.org\/10.1007\/s12325-009-0075-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}